Alembic Pharmaceuticals Ltd vs Alkem Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Apr 02, 2026

Key Highlights

The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 653.8 as of 02 Apr 16:01 . The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 16.5 on March 2021 to 31.3 on March 2025 . This represents a CAGR of 13.66% over 5 yearsThe P/E Ratio of Alkem Laboratories Ltd changed from 20.9 on March 2021 to 26.9 on March 2025 . This represents a CAGR of 5.18% over 5 years The Market Cap of Alembic Pharmaceuticals Ltd changed from ₹ 18971 crore on March 2021 to ₹ 18265 crore on March 2025 . This represents a CAGR of -0.76% over 5 yearsThe Market Cap of Alkem Laboratories Ltd changed from ₹ 33145 crore on March 2021 to ₹ 58347 crore on March 2025 . This represents a CAGR of 11.97% over 5 years The revenue of Alembic Pharmaceuticals Ltd for the Dec '25 is ₹ 1891 crore as compare to the Sep '25 revenue of ₹ 1918 crore. This represent the decline of -1.39% The revenue of Alkem Laboratories Ltd for the Dec '25 is ₹ 3879 crore as compare to the Sep '25 revenue of ₹ 4104 crore. This represent the decline of -5.48% The ebitda of Alembic Pharmaceuticals Ltd for the Dec '25 is ₹ 264.93 crore as compare to the Sep '25 ebitda of ₹ 324.02 crore. This represent the decline of -18.24% The ebitda of Alkem Laboratories Ltd for the Dec '25 is ₹ 918.31 crore as compare to the Sep '25 ebitda of ₹ 1024 crore. This represent the decline of -10.36% The net profit of Alembic Pharmaceuticals Ltd changed from ₹ 134.54 crore to ₹ 131.95 crore over 7 quarters. This represents a CAGR of -1.10% The net profit of Alkem Laboratories Ltd changed from ₹ 550.24 crore to ₹ 653.53 crore over 7 quarters. This represents a CAGR of 10.33% The Dividend Payout of Alembic Pharmaceuticals Ltd changed from 25.09 % on March 2021 to 42.97 % on March 2025 . This represents a CAGR of 11.36% over 5 yearsThe Dividend Payout of Alkem Laboratories Ltd changed from 21.28 % on March 2021 to 23.59 % on March 2025 . This represents a CAGR of 2.08% over 5 years .

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world.
The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited.
The company is engaged in pharmaceuticals business.
As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement.

About Alkem Laboratories Ltd

Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations.
The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. Alkem Laboratories Limited was incorporated as a private limited company on August 8, 1973 in Patna and subsequently became a deemed public limited company on October 26, 1988.
Pursuant to Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of the Company was changed to 'Alkem Laboratories Limited' with effect from October 26, 1988.

FAQs for the comparison of Alembic Pharmaceuticals Ltd and Alkem Laboratories Ltd

Which company has a larger market capitalization, Alembic Pharmaceuticals Ltd or Alkem Laboratories Ltd?

Market cap of Alembic Pharmaceuticals Ltd is 13,292 Cr while Market cap of Alkem Laboratories Ltd is 62,657 Cr

What are the key factors driving the stock performance of Alembic Pharmaceuticals Ltd and Alkem Laboratories Ltd?

The stock performance of Alembic Pharmaceuticals Ltd and Alkem Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alembic Pharmaceuticals Ltd and Alkem Laboratories Ltd?

As of April 2, 2026, the Alembic Pharmaceuticals Ltd stock price is INR ₹676.25. On the other hand, Alkem Laboratories Ltd stock price is INR ₹5240.45.

How do dividend payouts of Alembic Pharmaceuticals Ltd and Alkem Laboratories Ltd compare?

To compare the dividend payouts of Alembic Pharmaceuticals Ltd and Alkem Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.